Effects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines

Loss of TP53 and RB1 function have both been linked to poor response to DNA damaging drugs in breast cancer patients. We inactivated TP53 and/or RB1 by siRNA mediated knockdown in breast cancer cell lines varying with respect to ER/PgR and Her-2 status as well as TP53 and RB1 mutation status (MCF-7,...

Descripción completa

Detalles Bibliográficos
Autores principales: Huun, Johanna, Lønning, Per Eystein, Knappskog, Stian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439126/
https://www.ncbi.nlm.nih.gov/pubmed/28580174
http://dx.doi.org/10.1038/cddiscovery.2017.26

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439126/
https://www.ncbi.nlm.nih.gov/pubmed/28580174
http://dx.doi.org/10.1038/cddiscovery.2017.26

Ejemplares similares